Akkol, SevvalBozdemir, Enver2025-10-112025-10-1120251309-3878https://doi.org/10.18521/ktd.1443887https://search.trdizin.gov.tr/tr/yayin/detay/1321031https://hdl.handle.net/20.500.12684/21662Objective: The aim of the study is to analyze the costs of Chronic Obstructive Pulmonary Disease (COPD) from the perspective of the Social Security Institution (SSI). Method: In the research, data obtained retrospectively using the qualitative method were subjected to document analysis. The study covers 241 COPD patients in 2022 in the Chest Diseases unit of D & uuml;zce University Health Application and Research Center/Hospital. No sample was selected in the research, but the entire population was used. Data were subjected to multivariate regression analysis. Costs include examinations, medical supplies, medications, imaging and laboratory tests. Results: Of 130 outpatients, 110 (85%) were male, 20 (15%) were female, the mean age was 66.82 years, and outpatient treatment cost was 127.76h ($7.72)/patient. Of the 111 inpatients, 88 (79%) were male, 23 (21%) were female, the mean age was 70.19 years, and the mean duration of hospitalization was 7.08 days. The average total treatment cost of the clinic was 2,319.64h ($140.16)/patient. Of this, 1,059.97 h ($64.05) was for intervention, 267.62 h ($16.17) for medical supplies, 907.74 h ($54.85) for medication, and 499.98 h ($30.21) for investigations. It was determined that the gender, age, and hospitalization duration of the patients changed the treatment costs (p<0.05). In addition, it was determined that the SSI incurred an average annual drug cost of 6,321.84 h ($381.98). A total annual average cost of 9,184.90 h ($554.98) /patient was determined. Conclusions: The study found that treating COPD is a significant economic burden per patient for the SSI. A significant portion of this cost is comprised of medication expenses. This increases the lifetime costs of COPD. In order to reduce the cost of the disease, both necessary measures should beAtaken to reduce the risk of developing the disease, and lower-cost methods should be followed in the treatment of the disease.en10.18521/ktd.1443887info:eu-repo/semantics/closedAccessChest DiseasesCOPHCost of DiseaseArticle1721661751321031WOS:001520342200007N/A